Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German testicular cancer study group case series
Outcomes of multiply relapsed, refractory germ-cell tumour (GCT) patients remain poor with an overall survival (OS) of a few months only. Thus, new therapeutic advances are urgently needed. Cabazitaxel has shown preclinical activity in platinum-resistant GCT models. Here, we report the first clinica...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2020
|
| In: |
Journal of cancer research and clinical oncology
Year: 2019, Jahrgang: 146, Heft: 2, Pages: 449-455 |
| ISSN: | 1432-1335 |
| DOI: | 10.1007/s00432-019-03071-2 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00432-019-03071-2 |
| Verfasserangaben: | Christoph Oing, Marcus Hentrich, Anja Lorch, Dietrich Gläser, Holger Rumpold, Sebastian Ochsenreither, Stephan Richter, Annette Dieing, Stefanie Zschäbitz, Ronnie Rodrigues Pereira, Carsten Bokemeyer, Christoph Seidel |
| Zusammenfassung: | Outcomes of multiply relapsed, refractory germ-cell tumour (GCT) patients remain poor with an overall survival (OS) of a few months only. Thus, new therapeutic advances are urgently needed. Cabazitaxel has shown preclinical activity in platinum-resistant GCT models. Here, we report the first clinical case series of cabazitaxel treatment for platinum-refractory GCT. |
|---|---|
| Beschreibung: | Published: 14 December 2019 Gesehen am 24.06.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1432-1335 |
| DOI: | 10.1007/s00432-019-03071-2 |